Price
No data yet.
Social Signal Score
Revenue
$4.02MCompany Profile
- CEO
- David Christensen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Beta
- 1.22
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- -24.76
Financials
Revenue
$4.02M+28448.5%Net Income
$-2.91MEBITDA
$656.8KFree Cash Flow
$288.5KEPS (diluted)
$-0.22Shares Outstanding (diluted)
13.22M+646.2%Operating Expenses
$1.87MCash & Debt
$1.32MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $5.10M | $-7.81M | $-0.62 |
| 2024 | $4.11M | $-5.56M | $-0.44 |
| 2023 | $2.41M | $-9.81M | $-0.79 |
| 2022 | $1.53M | $-5.49M | $-0.45 |
| 2021 | $437.9K | $-12.88M | $-1.12 |
| 2020 | $55.1K | $-5.90M | $-0.63 |
| 2019 | $30.1K | $-2.51M | $-0.47 |
| 2018 | $50.1K | $-2.06M | $-0.50 |
| 2017 | $29.2K | $-377.0K | $-0.11 |
| 2016 | $0.00 | $-4.21M | $-2.34 |
| 2015 | $5.4K | $-1.93M | $-7.82 |
| 2014 | $0.00 | $-4.55M | $-15.60 |
Valuation
RMTGhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
110+37.50%Social Signal Score
Mentions (12)
- Newsaccessnewswire.com·31d ago·Positive
RMTG's ISSCA Division Returns to São Paulo for a Second Brazil Congress, November 20-21 A second Brazil event in a single year - a frequency ISSCA has not previously applied - underscores Brazil's priority alongside Cellgenic's permanent operations there. MIAMI, FL / ACCESS Newswire / October 22, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a Regenerative Medicine Company.
View source ↗ - Newsaccessnewswire.com·33d ago·Neutral
RMTG to Go Ringside at BKFC This Weekend to Capture Content for Its "RMTG Brief" Investor-Awareness Campaign MIAMI, FL / ACCESS Newswire / October 20, 2026 / Regenerative Medical Technology Group Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced that its content team will be ringside at this Saturday's Bare Knuckle Fighting Championship (BKFC) event to capture footage for "RMTG Brief…
View source ↗ - Newsaccessnewswire.com·48d ago·Positive
RMTG Broadens Longevity Footprint With New ISSCA Certification Across Adjunctive Therapies New ISSCA curriculum covers multiple adjunctive technologies used in longevity-focused practices and is intended to complement clinical capabilities Cellular Hope Institute is developing. MIAMI, FL / ACCESS Newswire / October 5, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem…
View source ↗ - Newsaccessnewswire.com·52d ago·Positive
RMTG Expands Peptide Education Platform With ISSCA Peptide Certification 2.0 and New Physician Reference Guides The upgraded program complements Cellgenic's expanding peptide training product portfolio and is intended as a current example of RMTG's education-to-product operating model. MIAMI, FL / ACCESS Newswire / October 1, 2026 / Oct 1, 2026, Regenerative Medical Technology Group Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned su…
View source ↗ - Newsaccessnewswire.com·66d ago·Neutral
RMTG's ISSCA Division Launches Integrative Fellowship in Point-of-Care Regenerative Medicine through ISSCA AI(TM) Strategy ISSCA's most comprehensive credential to date integrates regenerative medicine, biotechnology, longevity medicine, and artificial intelligence - a durable, multi-year physician-relationship asset. New multi-component fellowship is designed to combine regenerative medicine, biotechnology, longevity medicine, clinical implementation, and physician-controlled clinical-intellige…
View source ↗ - Newsaccessnewswire.com·69d ago·Neutral
…n - with the physician remaining the decision-maker MIAMI, FL / ACCESS Newswire / September 14, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), operating through its wholly owned subsidiary Global Stem Cells Group, today issued an expanded technology, data, and commercial overview of the ISSCA AI™ Clinical Intelligence Platform. The update describes a more fully specified, physician-facing system for regenerative and longevity medicine: clinics can uplo…
View source ↗ - Newsaccessnewswire.com·82d ago·Neutral
RMTG's Cellgenic Commences Commercial Activity in Peru, Extending Its Latin American Footprint Peru becomes the newest addition to Cellgenic's Latin American commercial network - one of three coordinated market initiatives across the region, subject to applicable local regulatory requirements. MIAMI, FL / ACCESS Newswire / September 1, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subs…
View source ↗ - Newsaccessnewswire.com·87d ago·Neutral
RMTG's Cellgenic Division Introduces MUSE Cell Product Line Across Four International Regions A second cellular-technology launch in close succession broadens Cellgenic's portfolio into Latin America, the Middle East, Europe, and Southeast Asia, demonstrating a repeatable product-development motion. MIAMI, FL / ACCESS Newswire / August 27, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned …
View source ↗ - Newsaccessnewswire.com·88d ago·Negative
RMTG Acquires RMTG.com Domain and Launches New Investor-Focused Website, Advancing Shareholder Engagement New Website Serves as a Central Source for Investor Information and Timely Disclosure; Investor Inquiries Directed to ir@rmtg.com MIAMI, FL / ACCESS Newswire / August 26, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced that it has a…
View source ↗ - Newsaccessnewswire.com·90d ago·Neutral
RMTG's Cellgenic Division Launches Natural Killer (NK) Cell Product Line for International Markets New NK cell platform extends RMTG's cellular-technology portfolio into immunology-adjacent applications, with an initial commercial focus on Latin America and Southeast Asia. MIAMI, FL / ACCESS Newswire / August 24, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cell…
View source ↗ - Newsaccessnewswire.com·94d ago·Negative
RMTG More Than Quadruples Revenue and Gross Profit in Q2 2026 Versus Q2 2025, With Operating Income Surpassing $560,000 Continued Acceleration in 2026 With Record Revenue, Expanding Margins, Growth in Operating Profit, and Accelerating Training and Product Supply Sales MIAMI, FL / ACCESS Newswire / August 20, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Gr…
View source ↗ - Newsaccessnewswire.com·95d ago·Neutral
RMTG Provides Details for First-Ever Investor Call to Answer Shareholder Questions Company Announces Date, Time and Connection Details for Its Inaugural Investor Call Following a Strong First Half of 2026 MIAMI, FL / ACCESS Newswire / August 19, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced the connection details for its first-ever in…
View source ↗
Insider trading
Open-market buys and sells by RMTG officers and directors.
No open-market trades in the recent filings. All 6 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
6 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RMTG.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
